UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported) February
15, 2007
Interpharm
Holdings, Inc.
(Exact
name of Registrant as specified in charter)
|
Delaware
|
|
0-22710
|
|
13-3673965
|
|
(State
or other jurisdic-
|
|
(Commission
|
|
(IRS
Employer
|
|
tion
of incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
| |
|
|
|
|
| |
|
|
|
|
|
75
Adams Avenue, Hauppauge, New York
|
|
11788
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant's
telephone number, including area code: (631)
952 0214
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
5.02 Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers.
On
January 23, 2007, the Interpharm Holdings, Inc.’s (the “Company”) Board of
Directors appointed Peter Giallorenzo as an Executive Vice President, effective
on that date, and as its Chief Financial Officer (“CFO”), effective February 15,
2007.
Mr.
Giallorenzo, 49, is a Certified Public Accountant with over twenty five years
of
management and financial experience for both public and private companies.
Prior
to joining the Company, Mr. Giallorenzo served for six years as Senior Vice
President Finance and CFO of Nice-Pak Products, Inc., a consumer and healthcare
products manufacturer. Mr. Giallorenzo also has experience in the generic
pharmaceutical business having served as CFO initially, and then Senior Vice
President and Chief Operating Officer of Taro Pharmaceutical Industries, Ltd.,
a
generic pharmaceutical product manufacturer.
In
connection with his employment with the Company, Mr. Giallorenzo entered into
an
employment agreement with the Company with a three year term. The other material
terms of the agreement are as follows: a base salary of $237,500 per year,
100,000 options to purchase Company common stock that are to vest over five
years or an economic equivalent in restricted common stock and an additional
100,000 options or an economic equivalent in restricted common stock which
will
vest upon the achievement of certain performance measures.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
INTERPHARM
HOLDINGS, INC.
|
| |
|
|
February
15, 2007
|
By:
/s/ Kenneth Cappel, Esq.
|
| |
Kenneth
Cappel, Esq.
|
| |
Executive
Vice President and General Counsel
|